Enbrel, Etanercept News

Receive a FREE Osteoarthritis of the knee pamphlet. Start here. Anyone just taking a low dosage of Prednisone to treat Rheumatoid Arthritis? 11/18/09 I am just taking 5 mg Prednisone for Rheumatoid Arthritis & I feel pretty good except sometimes very tired.

Although Stelara is entering a crowded treatment room for psoriasis, this first-in-class interleukin inhibitor could put the "no more tears" back in J&J's future - if successfully marketed to specialists, in particular dermatologists, as it is a novel and less cumbersome injectable than established biologics for psoriasis, the tumor necrosis ...

Establish a relationship with your doctor that works for you. I have recently experienced dark places on my lower gums.

Receive a FREE Osteoarthritis of the knee pamphlet. Start here. advice on medicines in rhemutoid arthiritis 11/18/09 mariam Topics: Medicines on Rhemutoid hi! I have tried humira, embrel and orencia along with methotrexate but still my sed rate does not go down and i am in lot of pain and stifness.

WALTHAM,A Mass. Biotech companies that manufacture a class of drugs used to treat autoimmune disorders stand to lose more than $9 billion in Europe and the United States by 2018 thanks to competition from biosimilars, according to a report.

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 98 percent of surveyed rheumatologists indicate they will prescribe Roche's Actemra, an interleukin-6 inhibitor, for the treatment of rheumatoid arthritis following the agent's expected launch in 2010.

A Swedish study has concluded that rheumatoid arthritis patients did not experience an increased cancer risk in the first 6 years of treatment with TNF blockers .

During the past decade, a new class of drugs, called TNF inhibitors, has improved the lives of tens of thousands of people who suffer from painful autoimmune diseases including rheumatoid arthritis, psoriatic arthritis, and Crohn's disease.

Oct. 29, 2009 -- Rheumatoid arthritis patients who take the biologic drugs Remicade , Humira , and Enbrel do not appear to have an increased risk for developing cancer in the first few years of use, researchers in Sweden report.

Treatment with tumor necrosis factor blockers doesn't increase rheumatoid arthritis patients' risk of cancer, new research has found.

A recent study by Swedish researchers found that rheumatoid arthritis patients did not experience an elevated cancer risk in the first 6 years after starting anti-tumor necrosis factor therapy.

Last week, Pfizer, the world's largest biopharmaceutical company, officially completed its merger with Wyeth, which produces some of the world's top-selling medicines, including Enbrel for rheumatoid arthritis and Prevnar, a vaccine against pneumococcal disease.

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of marketed and emerging TNF-alpha inhibitors and interleukin inhibitors will drive the psoriasis drug market to increase from $3 billion in 2008 to $5.2 billion in 2018 in the United States, France, ...

Cephalon, Inc. and BioAssets Development Corporation , a privately held biopharmaceutical company, today announced that the companies have signed an agreement that will provide Cephalon with an option to acquire BDC.

Back in the dim days of black-and-white television, one over-the-counter product that was frequently advertised claimed to help "the heartbreak of psoriasis." The phrase is no longer heard in commercials, but the heartbreak is still there.

As a treatment for rheumatoid arthritis, there is "moderate-level" evidence that the immunomodulator abatacept is safe and effective, conclude the co-authors of a Cochrane Intervention Review posted online October 4. Abatacept inhibits the co-stimulation of T cells and disrupts the inflammatory chain of events that lead to joint inflammation, pain ...

Main Category: Arthritis / Rheumatology Also Included In: Clinical Trials / Drug Trials Article Date: 23 Oct 2009 Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that tumor necrosis factor -alpha inhibitors will continue to dominate first- and second-line biologic ...

Back in the dim days of black-and- white television, one over-the-counter product that was frequently advertised claimed to help "the heartbreak of psoriasis." The phrase is no longer heard in commercials, but the heartbreak is still there.

Oct 19, 2009 - Idera Pharmaceuticals, Inc. today announced the presentation of preclinical data from studies of IMO-3100 in combination with Enbrel in a mouse model of arthritis.

Main Category: Arthritis / Rheumatology Also Included In: Clinical Trials / Drug Trials ; Conferences ; Pharma Industry / Biotech Industry Article Date: 20 Oct 2009 - 1:00 PDT New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis receiving SIMPONI every four weeks achieved sustained ...